Sanofi’s multiple sclerosis medicine tolebrutinib was recommended for approval by European regulators, a boost for the ...
By Marleen Kaesebier and Patricia Weiss ZURICH, April 22 (Reuters) - Swiss drugmaker Roche on Wednesday said it was ...
The Swiss drugmaker Roche presented the latest data for its experimental multiple sclerosis drug, setting the stage for the ...
A multiple sclerosis drug from Sanofi that was rejected late last year by the FDA found a warmer reception in Europe.
After a series of regulatory and clinical setbacks for Sanofi’s tolebrutinib, the French pharma has scored a victory for the ...
Cenrifki prevents MS disease progression and Itvisma delivers a healthy gene-to-cell nuclei, addressing the root cause of SMA.
A new method replicated the findings of a previous clinical trial of Tecfidera in people with relapsing-remitting MS, a study ...
The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of ocrelizumab for the treatment of ...
Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t be completed by the end of the year and a trial for a different form of MS ...
Medicaid coverage of highly effective disease-modifying therapies for MS varies widely across the U.S., with no coverage in ...
FRANKFURT (Reuters) -Swiss drugmaker Roche said on Monday that a late-stage trial testing its multiple sclerosis drug candidate fenebrutinib against the relapsing form of the disease achieved its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results